23andMe to Announce Q2 FY2025 Financial Results
Sunnyvale, California – 23andMe Holding Co. (Nasdaq: ME) has announced that it will publicly share its financial results for the second quarter of fiscal year 2025 (FY2025) before the market opens on the specified date. This announcement updates an earlier release, which mistakenly indicated the reporting would occur after the market closed. Investors and interested parties are encouraged to tune in for the conference call, which will take place at 8:00 a.m. Eastern Time on that day.
Conference Call Details
The company’s conference call, aimed at discussing the quarterly results, will be streamed live. Access to the webcast will be available on the day of the event, providing those interested with a platform to hear directly from company leaders about key financial metrics and business progression. A replay of the webcast will also be accessible shortly after the event concludes, ensuring that all stakeholders have an opportunity to listen in.
Engagement Through Say Technologies
In an innovative approach to shareholder engagement, 23andMe will leverage the Say Technologies platform. This method allows both retail and institutional shareholders to submit questions in advance of the earnings call. This initiative enhances transparency and gives shareholders a voice in matters that directly affect them. To participate, shareholders should visit the provided platform link, ensuring their questions are received before the Q&A session closes, which is 24 business hours prior to the conference call.
About 23andMe
23andMe is a pioneering company at the intersection of healthcare and genetics. Its mission focuses on empowering individuals to better understand their genetic makeup, which can lead to healthier lifestyle choices and informed health decisions. The company’s commitment to leveraging genetic insights is fundamental to its operations in both consumer healthcare and therapeutics, signifying its role in modern medicine.
Company’s Core Mission
As a leader in consumer genetics, 23andMe aims to transform public understanding of genetics. By offering accessible testing services, they provide insights that can enhance personal health and drive advancement in therapeutic solutions. The company continually invests in research and platforms that support this mission, contributing to a future where genetic literacy enables people to take charge of their health.
Future Plans and Developments
Looking ahead, 23andMe remains focused on expanding its service offerings and strategic partnerships. The company strives to continuously innovate within its proprietary research platform, which has the potential to significantly enhance the customer experience and improve outcomes in personalized medicine. Investors can look forward to updates on these developments during the upcoming earnings call.
Contact Information
For any investor-related inquiries, please contact:
Investor Relations: investors@23andme.com
For media inquiries, contact:
Media: press@23andme.com
Frequently Asked Questions
What is 23andMe announcing in their financial report?
23andMe will share the financial results for the second quarter of FY2025 alongside insights on their business progress during the earnings call.
When will the earnings call take place?
The earnings call is scheduled for 8:00 a.m. Eastern Time on the specified date, providing a platform for the company to discuss the financial outcomes.
How can shareholders ask questions during the call?
Shareholders can submit and upvote questions through the Say Technologies platform prior to the earnings call. The submission window will close 24 business hours before the event.
Where can I access the webcast?
The live webcast of the earnings call will be accessible on the day of the event. A replay will be available afterward for those who cannot attend live.
What does 23andMe specialize in?
23andMe focuses on consumer genetics and therapeutics, offering insights that empower individuals to make informed health decisions based on their genetic information.
